Summary: In this TIME Magazine article, the successful results of MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD are acknowledged as a “breakthrough” in medical research, as is a recent study involving psilocybin-assisted therapy for depression.
TIME notes that in the MAPS-sponsored study, “67% of the people who had taken MDMA no longer met the criteria for a PTSD diagnosis, compared with 32% of the placebo group.”
Originally appearing here.
